ABLi Therapeutics
Biotechnology Research
2 employees
- Employees
- 2
- Contacts
- 2
- Emails
- 2
- Phones
- 1
ABLi Therapeutics Overview
- Website
- ablitherapeutics.com
- Industry
- Biotechnology Research
- Employees
- 2
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
About ABLi Therapeutics
ABLi Therapeutics is a developing small molecule inhibitors to treat diseases resulting from Abelson Tyrosine Kinase dysfunction (Abl kinases or c-Abl). The Company is engineering its Abl kinase inhibitors to treat Parkinson’s disease, Parkinson’s-related neurodegenerative diseases and other neurological diseases associated with Abl kinase dysfunction inside and outside of the brain.
ABLi Therapeutics Contact Details
- People in AeroLeads
- 2
- With contact data
- 2
- Email contacts
- 2
- 100.0% coverage
- Phone contacts
- 1
- 50.0% coverage
ABLi Therapeutics Org Chart
Sample employees and titles| Name | Title | Location | Contact |
|---|---|---|---|
| Garth Lees-Rolfe | Chief Financial Officer, Abli | Boston, Massachusetts, United States |
Email
|
| Anastasia Daifotis | Independent Board Director, Physician | New York City Metropolitan Area, United States |
Email
Phone
|
Compare Similar Companies to ABLi Therapeutics
Verastem Oncology
Biotechnology Research
Oruka Therapeutics
Biotechnology Research
Stylus Medicine
Biotechnology Research
Palvella Therapeutics
Biotechnology Research
Inhibikase Therapeutics, Inc.
Pharmaceutical Manufacturing
Intrepid Labs
Biotechnology Research
Remedy Plan Therapeutics
Biotechnology
CVG Home Buyers LLC
Real Estate
SynthBiome Inc.
Biotechnology Research
EpiVax Therapeutics, Inc.
Biotechnology